Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 22fludarabine phosphate 17Cyclosporine 15Peripheral Blood Stem Cell Transplantation 14Methotrexate 14Filgrastim 14Whole-Body Irradiation 11Mycophenolic Acid 11Busulfan 11Antilymphocyte Serum 11Radiotherapy 8Melphalan 8Exercise 8Dexamethasone 8Cytarabine 8Asparaginase 8venetoclax 7blinatumomab 7Vincristine 7Etoposide 7Daunorubicin 7fludarabine 6Methylprednisolone 6Mercaptopurine 6Granulocyte Colony-Stimulating Factor 6Therapeutics 5Psychiatric Rehabilitation 5Prednisone 4Immunotherapy, Adoptive 4Cord Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Basiliximab × Clear all
NCT00594308 2014-10-06

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Indiana University

Phase NA Terminated
10 enrolled 11 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡